Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks Mixed, IAG Drops Despite Guidance Upgraded

Fri, 30th Oct 2015 08:31

LONDON (Alliance News) - Stocks in London opened mixed Friday, with IAG as the worst blue-chip performer even though it reported a rise in operating profit in the third quarter and upgraded its profit guidance for 2015.

The FTSE 100 index opened down 0.1% at 6,389.83 points, the FTSE 250 was flat at 17,108.13, while the AIM All-Share was up 0.1% at 741.28. In Europe, the CAC 40 in Paris was up up 0.5% and the DAX 30 in Frankfurt was up 0.4%.

International Consolidated Airlines Group, which on Thursday approved its first dividend payment since it was created in 2011, said its operating profit in the third quarter to the end of September was EUR1.25 billion, up from EUR900.0 million a year earlier and still up to EUR1.21 billion when excluding the contribution from Aer Lingus Group, the Irish flag carrier IAG acquired this year.

For the nine months to the end of September, operating profit for the group was up to EUR1.77 billion from EUR1.05 billion a year earlier, a 69% rise.

The strong results in the quarter meant IAG has upgraded its operating profit guidance for the full year to EUR2.25 billion to EUR2.30 billion, a firmer target than the previous guidance for profit to be in excess of EUR2.20 billion. The new guidance also excludes any contribution from Aer Lingus.

Shares in the British Airways and Iberia owner were down 4.6% at the open.

Meanwhile, Royal Bank of Scotland Group was down 1.1%. It reported improved third-quarter net profit, as it booked a big gain on the loss of control of Citizens, the US retail bank it is selling, but warned that the costs of restructuring and addressing past conduct and litigation are not about to go away.

The bank said it made a GBP952 million net profit in the three months to September 30, compared with GBP896 million in the corresponding quarter the prior year. That included a GBP1.15 billion gain on the loss of control of Citizens, and the bank also confirmed that it is set to sell its remaining 20.9% stake in that bank.

Citizens Financial Group on Thursday said that RBS is now expected to exit its remaining 20.9% stake in the US retail bank. According to Citizens, RBS has launched a registered underwritten public offering to sell all of its remaining 110.5 million shares in the bank. RBS had previously set out plans to divest the rest of its stake by the end of 2015.

RBS peer Barclays was down 0.9% after several price target cuts from JPMorgan, Goldman Sachs, Exane BNP and Societe Generale. The bank closed Thursday as the biggest faller after it missed market expectations and cut guidance for 2016, as its adjusted pretax profit fell in the third quarter.

In the FTSE 250, Vectura Group is the best performer, up 4.7%, after it said it has secured two milestone payments following an approval of an inhaler in the US and after hitting a development milestone in Europe.

It said the US Food and Drug Administration has approved the dual combination Utibron Neohaler and Seebri Neohaler products for the long-term treatment of patients with chronic obstructive pulmonary disease. The approval has triggered a USD22.5 million milestone payment to Vectura from Swiss pharmaceuticals giant Novartis, Vectura's partner on the product.

Separately, the group has been paid a USD750,000 cash milestone after a further development milestone was hit for its VR632 therapy in the European Union. VR632 is an asthma and COPD inhaled treatment therapy which users Vectura's dry powder inhaler and formulation technology.

Outside company news, the Bank of Japan said that its Monetary Policy Board, governed by Haruhiko Kuroda, decided by an 8-1 majority vote to keep its target of raising the monetary base at an annual pace of about JPY80 trillion. The bank also maintained its asset purchase program unchanged.

Some economists had hoped that the Bank of Japan would announce additional stimulus, as the domestic economy is still struggling with deflation and a fits-and-starts recovery. The yen firmed up in reaction to the decision and is currently trading at the upper 120-range against the dollar.

"The market response suggests markets content with the status quo and especially the option for more QE later as well as the BoJ's confidence in a growth turnaround," said Accendo Markets analyst Michael van Dulken.

"Not dissimilar to the hawkish Fed statement mid-week seeing the positive outlook on growth outweighing the prospect of higher rates on the horizon. Markets still like cheap money, but may be coming round to a return to preference for actual growth," van Dulken added.

The Japanese Nikkei 225 index closed Friday up 0.8%. In China, the Shanghai Composite finished down 0.1%, while the Hang Seng in Hong Kong ended down 0.8%.

Wall Street ended mostly lower Thursday, with the DJIA down 0.1%, the S&P 500 flat and the Nasdaq Composite down 0.4%.

Growth in US economic activity slowed in the third quarter, according to a report released by the Commerce Department on Thursday. The report said annualised real gross domestic product rose by 1.5% in the third quarter compared to the 3.9% jump seen in the second quarter. Economists had expected a 1.7% increase.

In the economic calendar Friday, eurozone inflation and unemployment are at 1000 GMT. In the US, personal consumption data is at 1230 GMT, the Chicago purchasing managers' index is at 1345 GMT, and the Reuters/Michigan consumer sentiment index is at 1400 GMT.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
25 Jan 2017 07:48

Vectura sales trigger $5m milestone receipt

(ShareCast News) - Vectura said on Wednesday that a sales milestone receipt of $5m has been triggered following confirmation by Novartis that EU/Rest of World combined net sales of its Seebri Breezhaler and Ultibro Breezhaler for the year to the end of December have reached $512m. The milestone will

Read more
24 Jan 2017 08:21

Vectura gets FDA investigational approval for VR647

(ShareCast News) - Device and formulation business for inhaled airways disease, Vectura Group, announced on Tuesday it has received an 'Investigational New Drug' approval from the US Food and Drug Administration for its VR647 product. The FTSE 250 firm said the approval will allow it to conduct a Ph

Read more
24 Jan 2017 07:47

Vectura Gets US Approval For Phase I Trial Of Asthma Treatment

Read more
11 Jan 2017 08:25

Vectura makes 'significant progess' in third quarter

(ShareCast News) - Inhaled airways disease device and formulation business Vectura Group announced an unaudited pre-close update on Wednesday, ahead of its results for the nine months to 31 December, due in March. The FTSE 250 company said that following the step-change in financial performance anno

Read more
11 Jan 2017 07:58

Respiratory Medicine-Maker Vectura Breathing Easy Over Revenue Targets

Read more
23 Dec 2016 10:03

WINNERS & LOSERS SUMMARY: PayPoint Sale And Special Payout Lift Shares

Read more
23 Dec 2016 07:57

Vectura Group signs development agreement with Mundipharma

(ShareCast News) - Inhaled airways disease device and formulation business Vectura Group announced on Friday that it has signed a development and licence agreement with Mundipharma International Corporation and a US independent associated company as the global development and commercialisation partn

Read more
22 Dec 2016 14:57

Vectura says Bayer completes EU approval procedure for alternative nebulised delivery

(ShareCast News) - Vectura said on Thursday that its partner Bayer has confirmed completion of the EU regulatory procedure that allows an alternative nebulised delivery for its currently-marketed product Ventavis using the London-listed company's smart nebuliser Fox device. Ventavis has been develop

Read more
21 Dec 2016 14:15

Vectura says Novartis signs US licensing agreement for COPD treatments

(ShareCast News) - Vectura announced that Swiss pharmaceutical company Novartis has signed a licensing agreement with Sunovion Pharmaceuticals for the US commercialisation rights to three treatments for chronic obstructive pulmonary disease for which it receives royalty revenues. Novartis, whose pro

Read more
8 Dec 2016 07:57

Vectura confirms positive study results for Ultibro Breezhaler

(ShareCast News) - Inhaled airways disease-focused business Vectura Group confirmed an announcement by its partner Novartis on Thursday. The FTSE 250 firm said the announcement was of positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequ

Read more
23 Nov 2016 07:40

Vectura earnings surge as Skyepharma merger creates step-change

(ShareCast News) - Inhaler maker Vectura's interim revenue have soared following the merger with rival Skyepharma and a launch of new products. For the six months ended 30 September, revenue increased 183% to £73.9m, compared to the same period last year, primarily due to the completion of the £441m

Read more
22 Nov 2016 07:41

TOP NEWS: Hikma Signs Development And Licensing Deal With Vectura

Read more
20 Nov 2016 15:57

Sunday newspaper round-up: OBR, Saudi Aramco, Tesco, BAT, bonds vigilantes

(ShareCast News) - The Office for Budget Responsibility is likely to cut its forecast for UK growth next year by the biggest margin since the peak of the eurozone debt crisis. Philip Hammond's Autumn Statement this week will see the Chancellor set out his multi-billion pound infrastructure plans and

Read more
17 Nov 2016 17:10

LONDON MARKET CLOSE: Strong US Data, Yellen Comments Point To Fed Hike

Read more
26 Oct 2016 14:14

Vectura climbs on positive read-across from Novartis, Singer upgrade

(ShareCast News) - Shares in medical device group Vectura were given a boost by expectations of foreign currency gains and investors reading across results from Novartis, with which the London-listed company is partnered on a handful of products. A third-quarter update from Novartis on Tuesday in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.